Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
184,457
clinical trials

Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Central Vermont Medical Center/National Life Cancer Treatment
mi
from
Berlin, VT
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Saint Vincent Healthcare
mi
from
Billings, MT
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Sanford Bismarck Medical Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Parkland Health Center-Bonne Terre
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Boulder
mi
from
Boulder, CO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Illinois CancerCare - Canton
mi
from
Canton, IL
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Southeast Cancer Center
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Oncology Associates at Mercy Medical Center
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Miami Valley Hospital South
mi
from
Centerville, OH
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Centralia Oncology Clinic
mi
from
Centralia, IL
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Carle on Vermilion
mi
from
Danville, IL
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Rose
mi
from
Denver, CO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
SCL Health Saint Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Broadlawns Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Bay Area Breast Surgeons Inc
mi
from
Emeryville, CA
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Blanchard Valley Hospital
mi
from
Findlay, OH
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Dayton Physicians LLC-Atrium
mi
from
Franklin, OH
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Saint Mary's Hospital and Regional Medical Center
mi
from
Grand Junction, CO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Mercy Health Saint Mary's
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Greenville Health System Cancer Institute-Greer
mi
from
Greer, SC
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Tripler Army Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Edwards Comprehensive Cancer Center
mi
from
Huntington, WV
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Centerpoint Medical Center LLC
mi
from
Independence, MO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Freeman Health System
mi
from
Joplin, MO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Research Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Kansas Institute of Medicine Cancer and Blood Center
mi
from
Lenexa, KS
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Geisinger Medical Oncology-Lewisburg
mi
from
Lewisburg, PA
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Lewistown Hospital
mi
from
Lewistown, PA
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Wilcox Memorial Hospital and Kauai Medical Clinic
mi
from
Lihue, HI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Littleton
mi
from
Littleton, CO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Mayo Clinic Health Systems-Mankato
mi
from
Mankato, MN
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Carle Physician Group-Mattoon/Charleston
mi
from
Mattoon, IL
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Middlesex Hospital
mi
from
Middletown, CT
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Mercy Hospital Oklahoma City
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Valley Radiation Oncology
mi
from
Peru, IL
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Aurora Cancer Care-Racine
mi
from
Racine, WI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Saint Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Greenville Health System Cancer Institute-Seneca
mi
from
Seneca, SC
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Welch Cancer Center
mi
from
Sheridan, WY
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Sanford Cancer Center-Oncology Clinic
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Memorial Hospital of South Bend
mi
from
South Bend, IN
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Aurora Medical Center in Summit
mi
from
Summit, WI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Hematology Oncology Associates of Central New York-Onondaga Hill
mi
from
Syracuse, NY
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Legacy Meridian Park Hospital
mi
from
Tualatin, OR
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Associates in Women's Health
mi
from
Wichita, KS
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KS
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KS
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Rice Memorial Hospital
mi
from
Willmar, MN
Click here to add this to my saved trials
Malignant Neoplasm Clinical Trial
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Metro Health Hospital
mi
from
Wyoming, MI
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 12/31/1969
Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 12/31/1969
Investigational Site - Detroit
mi
from
Detroit, MI
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 12/31/1969
Investigational Site - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 12/31/1969
Investigator Site - Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 12/31/1969
Morristown
mi
from
Morristown, NJ
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 12/31/1969
Investigator Site - San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 12/31/1969
Investigational Site - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Myelodysplastic Syndromes Clinical Trial
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Myelodysplastic Syndromes Clinical Trial
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Colorado Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Myelodysplastic Syndromes Clinical Trial
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Orthopedics / Podiatry, Other, Reproductive Clinical Trial
Tranexamic Acid in Adult Spinal Deformity Surgery
Status: Enrolling, Phase III
Updated: 12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Diabetes Clinical Trial
A Clinical Study to Collect Calibration & Performance Data of the KBS Systems 1.0 Non-Invasive Glucose Monitoring Device
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
Parkinson Disease Clinical Trial
Effects of Osteopathic Manipulative Treatment (OMT) on Gait Biomechanics in Parkinson's Disease
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Gastroenterology Clinical Trial
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [EXPEDITION]
Status: Enrolling, Phase II
Updated: 12/31/1969
The Center For Clinical Trials
mi
from
Biloxi, MS
Click here to add this to my saved trials
Bacterial Infections Clinical Trial
Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection
Status: Enrolling, Phase I
Updated: 12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Clostridium Difficile Clinical Trial
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
Status: Enrolling, Phase II
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Spinal Stenosis Clinical Trial
Post-Approval 'Real Conditions of Use' Study
Status: Enrolling
Updated: 12/31/1969
NorthShore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Sleep Restriction Clinical Trial
Hormonal Mechanisms of Sleep Restriction - Axis Study
Status: Enrolling, Phase I
Updated: 12/31/1969
Los Angeles Biomedical Research Institute
mi
from
Torrance, CA
Click here to add this to my saved trials
Peripheral Vascular Disease Clinical Trial
JET-RANGER Trial - JETStream Atherectomy With Adjunctive Paclitaxel-Coated Balloon Angioplasty vs Plain Old Balloon Angioplasty Followed by Paclitaxel-Coated Balloon
Status: Enrolling
Updated: 12/31/1969
Midwest Cardiovascular Research Foundation
mi
from
Davenport, IA
Click here to add this to my saved trials
Psychiatry / Psychology Clinical Trial
Study of Antibody for Methamphetamine Outpatient Therapy
Status: Enrolling, Phase I, II
Updated: 12/31/1969
PRA Health Sciences
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hematology Clinical Trial
Shared-Decision Making for Hydroxyurea
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Autism Spectrum Disorder Clinical Trial
Mindfulness for Parents of Children With Autism Spectrum Disorder Autism Spectrum Disorder
Status: Enrolling
Updated: 12/31/1969
Loma Linda University
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Modern Research Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Johnson Dermatology
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Alliance Research Centers
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Dermatology Specialist
mi
from
Louisville, KY
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Park Avenue Dermatology
mi
from
Orange Park, FL
Click here to add this to my saved trials
Alopecia Areata Clinical Trial
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Austin Institute for Clinical Research, Inc.
mi
from
Pflugerville, TX
Click here to add this to my saved trials
Attention Deficit Hyperactivity Disorder Clinical Trial
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Attention Deficit Hyperactivity Disorder Clinical Trial
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
Status: Enrolling, Phase III
Updated: 12/31/1969
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Attention Deficit Hyperactivity Disorder Clinical Trial
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
Status: Enrolling, Phase III
Updated: 12/31/1969
BioBehavioral Research of Austin
mi
from
Austin, TX
Click here to add this to my saved trials
Attention Deficit Hyperactivity Disorder Clinical Trial
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Attention Deficit Hyperactivity Disorder Clinical Trial
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
Status: Enrolling, Phase III
Updated: 12/31/1969
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials